Oxygen Biotherapeutics posts clinical results

Marketer of Dermacyte skin-care line - which delivers high levels of oxygen to skin to detoxify cells and prevent collagen breakdown, the company says - announces results from eight-week study evaluating use of its Dermacyte Oxygen Concentrate in 36 women ages 39 to 63 with mild to moderate facial wrinkles. Durham, N.C.-based firm says 80% of participants experienced at least one grade of improvement on the Fitzpatrick Wrinkle Assessment Scale, which measures wrinkle depth and the breakdown of tissues that leads to reduced elasticity. According to Oxygen Biotherapeutics, 97% improved at least one grade, compared with baseline photos, on the Global Improvement Aesthetic Scale, and 84% reported a similar outcome based on self-perception of GIAS. "We are pleased that the findings of this study ... showed promising results for nearly all patients," says company's Chief Medical Officer Gerald Klein. Dermacyte Oxygen Concentrate is the first product in a broad and diverse cosmetics line," according to Oxygen Biotherapeutics, which over the long term is developing medical products for delivering oxygen in cases of traumatic brain injury, decompression sickness and topical wounds (1"The Rose Sheet" Nov. 2, 2009). The concentrate sells online for $84 along with company's recently launched Oxygenating Eye Complex, priced at $120